논문번호 | 227 | ||
논문제목(영문) | Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type I Receptor Blockers in ST-Segment Elevation Myocardial Infarction After Successful Percutaneous Coronary Intervention with Drug-Eluti | ||
국내외구분 | 국외 | SCI여부 | SCI |
연구책임자역할 | 공저자 | ||
주저자명 | Yong Hoon Kim | ||
교신저자명 | Yong Hoon Kim | ||
공동저자명 | Ae-Young Her,Myung Ho Jeong,Byeong-Keuk Kim,Seung-Yul Lee,Sung-Jin Hong,Dong-Ho Shin,Jung-Sun Kim,Young-Guk Ko,Donghoon Choi,Myeong-Ki Hong,Yangsoo Jang | ||
게제년월일 | 2019-01-10 | ||
ISSN | 1573-7241 | ||
Impact Factor | 4.069 | ||
학술지명 | Cardiovasc Drugs Ther | ||
서지사항 | 0집 / 33권 / 1호, 페이지(55 - 67) | ||
요약초록문 (Abstract) 입력 |
Abstract Background/Aims Limited comparative data concerning long-term clinical outcomes of combination therapy between betablockers (BB) with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) therapy in patients with ST-segment elevation myocardial infarction (STEMI) are available. We thought to compare 2-year major clinical outcomes between BB with ACEI and BB with ARB therapy in patients with STEMI after successful percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Methods 13,873 STEMI patients who underwent successful PCI with DES were enrolled and divided into two groups as the BB with ACEI group (n = 10,393) and the BB with ARB group (n = 3480). The clinical endpoint was the occurrence of major adverse cardiac events (MACE) defined as all-cause death, cardiac death (CD), recurrent myocardial infarction (re-MI), total coronary revascularization (target lesion revascularization [TLR], target vessel revascularization [TVR], non-TVR) during the 2- year follow-up period. Results After propensity score-matched (PSM) analysis, two PSM groups (3296 pairs, n = 6592, C-statistic = 0.675) were generated. Although the incidences of re-MI, TLR, and TVR were similar, the incidences of MACE (8.3% vs. 6.8%, log-rank p = 0.038, hazard ratio [HR] 1.210, 95% confidence interval [CI] 1.010–1.451, p = 0.039), all-cause death, CD, total revascularization, and non-TVR of the BB with ARB group were significantly higher than the BB with ACEI group after PSM. In addition, diabetes and multivessel disease were significant predictors for non-TVR. Conclusions The combination BB with ACEI may be beneficial for reducing MACE in STEMI patients after successful PCI with DES than the BB with ARB. |
||
파일 |
C227. Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme I~.pdf (1,020.3K) DATE : 2021-06-06 21:14:15 |
전라남도 장성군 남면 삼태리 산 109 나노바이오연구원 3층 306호 TEL : 061-392-6243 Fax: 061-392-6243
Copyright ⓒ 2014 Korea Cardiovascular Stent Research Institute. All right Reserved